Security Snapshot

IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) Institutional Ownership

CUSIP: 46333X108

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

195

Shares (Excl. Options)

153,956,131

Price

$3.37

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / Class A Common Stock
Symbol
IRWD on Nasdaq
Shares outstanding
163,317,295
Price per share
$3.53
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
153,956,131
Total reported value
$518,987,593
% of total 13F portfolios
0%
Share change
+6,460,716
Value change
+$36,442,829
Number of holders
195
Price from insider filings
$3.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • IRWD - IRONWOOD PHARMACEUTICALS INC - Class A Common Stock is tracked under CUSIP 46333X108.
  • 195 institutions reported positions in Q4 2025.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 195 to 54 between Q4 2025 and Q1 2026.
  • Reported value moved from $518,987,593 to $13,124,006.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 195 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 46333X108?
CUSIP 46333X108 identifies IRWD - IRONWOOD PHARMACEUTICALS INC - Class A Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10% +2.1% $10,855,426 +$338,999 16,202,129 +3.2% The Vanguard Group 30 Jun 2025
ARMISTICE CAPITAL, LLC 9.8% +17% $82,368,500 +$11,950,500 16,025,000 +17% Armistice Capital, LLC 31 Dec 2025
BlackRock, Inc. 7.1% $9,930,271 11,284,399 BlackRock, Inc. 28 Feb 2025
BANK OF AMERICA CORP /DE/ 6.1% -19% $34,967,866 -$7,103,931 9,962,355 -17% BANK OF AMERICA CORP /DE/ 31 Mar 2026
Sarissa Capital Management LP 5.8% $31,735,012 9,444,944 Alexander J. Denner 17 Mar 2026
RENAISSANCE TECHNOLOGIES LLC 5.4% $7,565,534 8,597,198 Renaissance Technologies LLC 15 May 2024
STATE STREET CORP 2.2% -60% $3,078,494 -$4,250,865 3,498,289 -58% STATE STREET CORPORATION 31 Mar 2025
BARCLAYS PLC 2% -70% $4,149,704 -$10,435,649 3,167,713 -72% Barclays PLC 30 Sep 2025
Pacer Advisors, Inc. 1.1% -89% $1,574,406 -$8,748,672 1,789,098 -85% Pacer US Small Cap Cash Cows ETF 31 Mar 2025

As of 31 Dec 2025, 195 institutional investors reported holding 153,956,131 shares of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD). This represents 94% of the company’s total 163,317,295 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.8% 16,025,000 -0.77% 1.3% $54,004,250
VANGUARD GROUP INC 9.8% 15,958,196 -0.71% 0% $53,779,120
Sarissa Capital Management LP 9.7% 15,919,435 0% 24% $53,648,496
BlackRock, Inc. 7.8% 12,784,806 +6% 0% $43,084,796
BANK OF AMERICA CORP /DE/ 7.1% 11,521,660 -1.5% 0% $38,827,995
RENAISSANCE TECHNOLOGIES LLC 5% 8,204,973 -1.8% 0.04% $27,650,759
ACADIAN ASSET MANAGEMENT LLC 4% 6,457,817 -0.69% 0.04% $21,746,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3% 4,975,939 +1.2% 0% $16,768,914
AQR CAPITAL MANAGEMENT LLC 2.9% 4,723,531 -12% 0.01% $15,918,299
MARSHALL WACE, LLP 2.7% 4,424,002 +41% 0.01% $14,908,888
STATE STREET CORP 2.7% 4,411,222 +40% 0% $14,865,818
GEODE CAPITAL MANAGEMENT, LLC 2.2% 3,623,534 +0.24% 0% $12,213,817
FEDERATED HERMES, INC. 2% 3,318,137 +54% 0.02% $11,182,122
TWO SIGMA ADVISERS, LP 1.9% 3,140,100 -5.3% 0.02% $10,582,137
TWO SIGMA INVESTMENTS, LP 1.7% 2,853,205 +13% 0.01% $9,615,301
JANE STREET GROUP, LLC 1.7% 2,819,562 +21% 0.01% $9,501,924
JACOBS LEVY EQUITY MANAGEMENT, INC 1.7% 2,759,667 +44% 0.04% $9,300,078
Connor, Clark & Lunn Investment Management Ltd. 1.2% 1,990,927 -7.9% 0.02% $6,709,424
Qube Research & Technologies Ltd 1% 1,681,229 -40% 0.01% $5,665,742
GOLDMAN SACHS GROUP INC 0.78% 1,275,315 +18% 0% $4,297,812
NORTHERN TRUST CORP 0.76% 1,233,685 -8% 0% $4,157,518
Hillsdale Investment Management Inc. 0.71% 1,156,378 0.11% $3,896,994
DEUTSCHE BANK AG\ 0.68% 1,109,924 -27% 0% $3,740,444
LAZARD ASSET MANAGEMENT LLC 0.61% 1,000,445 0.01% $3,371,500
RAYMOND JAMES FINANCIAL INC 0.53% 869,826 +5681% 0% $2,931,314

Institutional Holders of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 3,747,933 $13,124,006 +$5,476,582 $3.51 54
2025 Q4 153,956,131 $518,987,593 +$36,442,829 $3.37 195
2025 Q3 148,541,007 $194,617,095 +$6,212,194 $1.31 160
2025 Q2 146,448,573 $105,056,220 -$19,990,203 $0.72 151
2025 Q1 155,587,802 $228,692,691 -$26,001,186 $1.47 200
2024 Q4 164,213,918 $727,463,387 +$1,737,232 $4.43 222
2024 Q3 163,472,233 $673,496,034 -$53,233,700 $4.12 218
2024 Q2 171,468,668 $1,117,746,593 -$10,390,681 $6.52 226
2024 Q1 172,118,333 $1,499,071,284 +$34,523,403 $8.71 259
2023 Q4 164,989,974 $1,887,503,875 +$27,460,717 $11.44 248
2023 Q3 162,344,641 $1,563,374,016 -$47,770,085 $9.63 248
2023 Q2 166,095,520 $1,767,006,761 +$4,551,974 $10.64 249
2023 Q1 165,499,147 $1,741,215,310 -$25,432,141 $10.52 253
2022 Q4 167,942,496 $2,080,711,382 -$11,969,237 $12.39 248
2022 Q3 169,832,029 $1,759,668,119 -$66,873,989 $10.36 234
2022 Q2 175,222,861 $2,020,512,624 +$105,001,683 $11.53 229
2022 Q1 166,602,554 $2,094,673,928 -$62,666,606 $12.58 205
2021 Q4 171,908,670 $2,002,842,425 -$78,175,850 $11.66 206
2021 Q3 177,433,352 $2,315,405,743 +$38,243,173 $13.06 216
2021 Q2 174,523,300 $2,245,931,885 +$54,432,994 $12.87 200
2021 Q1 171,145,457 $1,913,286,723 -$10,293,889 $11.18 202
2020 Q4 171,628,514 $1,954,636,964 -$289,602 $11.39 191
2020 Q3 179,160,124 $1,611,634,384 -$60,043,147 $9.00 183
2020 Q2 178,119,023 $1,838,125,889 +$1,165,854 $10.32 196
2020 Q1 178,568,993 $1,801,785,844 +$4,161,742 $10.09 186
2019 Q4 177,455,640 $2,362,005,410 +$49,445,414 $13.31 191
2019 Q3 173,764,399 $1,491,782,455 +$101,224,965 $8.58 156
2019 Q2 161,310,235 $1,764,640,729 +$57,814,939 $10.94 148
2019 Q1 154,995,090 $2,094,495,667 +$91,122,285 $13.53 150
2018 Q4 149,504,826 $1,548,336,251 -$71,151,637 $10.36 141
2018 Q3 144,665,764 $2,670,486,249 -$61,027,521 $18.46 149
2018 Q2 148,813,231 $2,845,437,392 -$59,848,588 $19.12 145
2018 Q1 152,306,846 $2,350,190,262 -$1,008,869 $15.43 145
2017 Q4 152,837,109 $2,291,153,384 -$72,488,750 $14.99 157
2017 Q3 157,184,610 $2,478,904,357 +$150,604,537 $15.77 145
2017 Q2 147,586,787 $2,784,285,643 +$174,107,575 $18.88 165
2017 Q1 146,394,957 $2,497,507,218 +$313,109,692 $17.06 158
2016 Q4 140,093,291 $2,142,057,976 +$7,058,282 $15.29 159
2016 Q3 138,112,999 $2,188,767,596 +$19,185,042 $15.88 150
2016 Q2 137,183,569 $1,793,474,568 -$46,641,420 $13.07 142
2016 Q1 141,086,992 $1,542,611,000 +$6,575,341 $10.94 133
2015 Q4 140,004,988 $1,623,135,302 -$10,046,894 $11.59 133
2015 Q3 141,087,024 $1,469,578,326 -$31,592,141 $10.42 129
2015 Q2 143,581,013 $1,730,907,955 +$111,334,758 $12.06 137
2015 Q1 133,635,220 $2,138,495,680 +$8,239,322 $16.00 142
2014 Q4 133,616,046 $2,046,265,589 +$20,104,400 $15.32 129
2014 Q3 131,914,423 $1,709,440,539 +$65,713,386 $12.96 138
2014 Q2 126,250,568 $1,934,608,469 -$76,713,665 $15.33 136
2014 Q1 131,861,633 $1,624,155,433 +$224,093,523 $12.32 135
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .